home / stock / lly / lly articles

LLY Articles, Eli Lilly and Company - From 03/26/24

Stock Information
Company Name: Eli Lilly and Company
Stock Symbol: LLY
Market: NYSE
Website: lilly.com
Menu
LLY LLY Quote LLY Short LLY News LLY Articles LLY Message Board
Get LLY Alerts

News, Short Squeeze, Breakout and More Instantly...
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly | Benzinga

Monday, Biohaven’s (NYSE:BHVN) CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company...
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In' | Benzinga

Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer. &quo...

Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry | Benzinga

In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...

Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge | Benzinga

Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S...
Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health | Benzinga

In a significant development, Medicare may extend coverage for Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (sem...

Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions | Benzinga

Eli Lilly and Co. (NYSE:LLY) enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound — the latter already recording stellar sal...

Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On' | Benzinga

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter. "We ...
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments | Benzinga

Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash p...

US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy | Benzinga

Eli Lilly And Co’s (NYSE:LLY) much-in-demand weight-loss drug Zepbound (tirzepatide) surged ahead with 77,590 new prescriptions in the U...

Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 20 Years | Benzinga

Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return o...
Previous 10 Next 10